TGA approval for Pfizer COVID-19 vaccine booster dose in Australia
The Therapeutic Goods Administration (TGA) has approved a booster dose of the Pfizer COVID-19 vaccine for individuals 18 years and older in Australia.
The TGA approval means that the Pfizer COVID-19 vaccine has been found safe and effective to boost protection for individuals aged 18 years and older through a third booster dose provided at least six months after the completion of a COVID-19 vaccine primary course of two doses. The primary course can be of any of the COVID-19 vaccine registered for use in Australia.
People remain fully vaccinated with two doses of TGA approved COVID-19 vaccines and the commencement of booster doses will provide additional protection and peace of mind for Australians.
Subject to final advice provided to the Government by the Australian Technical Advisory Group on Immunisation (ATAGI), it is expected that a general population booster program will commence no later than 8 November with original priority groups, including people in aged care and disability care settings, to be offered the option to receive a booster as a priority.
The Government also expects that Moderna will shortly apply to the TGA for registration of booster doses for their vaccine.
Since 11 October, Australians who are severely immunocompromised have been able to receive a third COVID-19 vaccine dose to boost their protection against COVID-19 to the highest level.